Sermonix to Present Poster at ENDO 2019 on Lasofoxifene’s ‘Potent Anti-Tumor Activity’ in ESR1 Hormone-Resistant Breast Cancer COLUMBUS, Ohio, March 04, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...

Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer COLUMBUS, Ohio, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...

Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer at San Antonio Breast Cancer Symposium Posters to be displayed at Dec. 4-8 conference address introduction of Phase 2 study of investigational drug lasofoxifene, its effect on breast cancer and lung and liver metastasis in an in vivo...

Sermonix Launches Phase 2 Trial to Evaluate Investigational Oral Lasofoxifene as a Targeted Precision Treatment for Women With ESR1 Mutations in Metastatic Breast Cancer COLUMBUS, Ohio, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific...